Protective efficacy of cationic-PLGA microspheres loaded with DNA vaccine encoding the sip gene of Streptococcus agalactiae in tilapia

Ma, Yuanfang; Hao, Ke; Liang, Zhiling; Ma, Jin-Yeul; Liang, Hao; Liu, Zhenxing

doi:10.1016/j.fsi.2017.05.003

Cited by 22 publications

(20 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…linear B cell epitope prediction was assessed and identified 11 potent epitopes from 5 common immunogenic and virulence proteins that were present in serotypes Ia and III. The previous studies supported that one of the chosen proteins, Sip, represented a highly conserved protein among GBS isolates and showed cross-protective immunity against GBS infections 11,13,14,31 . Prediction of candidate antigenic proteins can be used to select the bacterial strains that carry antigenic genes, as well as to determine high expression levels in the target host and the accessibility of particular antigens in host organisms 16 .…”

Section: Discussionsupporting

confidence: 65%

“…Numerous effective single-serotype GBS vaccines have been reported, including vaccines for controlling streptococcosis in tilapia 10,11,13,14,17,37,38 . However, it is known that single-serotype whole-cell inactivated vaccines have limitations during cross-prevention against different serotypes.…”

Section: Discussionmentioning

confidence: 99%

“…Although formalin-killed vaccines generally provide highly protective effects compared with those of subunit vaccines and DNA vaccines, the subunit and DNA vaccines may replace the original formalin-killed vaccines or inactivated vaccines due to their promising efficacy, which are similar to those of inactivated vaccines, and longer shelf life 18,33 . Evidence suggests that DNA and subunit vaccines can efficiently trigger the immune system and promote protective efficacy, with an RPS value greater than 50% 11,13,14,17 . Nevertheless, these vaccines have limitations, such as their mass production costs, and they may require various optimizations to obtain the highest stable storage conditions 18,41 .…”

Section: Discussionmentioning

confidence: 99%

“…For example, C-β protein (BAC) can lead to antibody production through Fc region binding of human IgA 42 . Sip protein has been shown to mediate protection against streptococcal infection 11,13,14 . Additionally, the chosen immunogenic protein should be conserved among Streptococcus spp., so it would be suitable for application in cross-reactive prevention among S. agalactiae serotypes 11,43 .…”

Section: Discussionmentioning

confidence: 99%

“…island (PI)-1 ancillary protein 1 15 , CAMP factor, R5 protein, enolase, hemolysin (cyLE) 16 , fibrinogen-binding protein A (FbsA) 17 , and surface immunogenic protein (Sip) 14 .…”

mentioning

confidence: 99%

See 4 more Smart Citations

Novel Chimeric Multiepitope Vaccine for Streptococcosis Disease in Nile Tilapia (Oreochromis niloticus Linn.)

Pumchan

Krobthong

Roytrakul

et al. 2020

Sci Rep

View full text Add to dashboard Cite

Streptococcus agalactiae is a causative agent of streptococcosis disease in various fish species, includingnile tilapia (Oreochromis niloticus Linn.). Vaccination is an effective disease prevention and control method, but limitations remain for protecting against catastrophic mortality of fish infected with different strains of streptococci. Immunoproteomics analysis of S. agalactiae was used to identify antigenic proteins and construct a chimeric multiepitope vaccine. Epitopes from five antigenic proteins were shuffled in five helices of a flavodoxin backbone, and in silico analysis predicted a suitable RnA and protein structure for protein expression. 45F2 and 42E2 were identified as the best candidates for a chimeric multiepitope vaccine. Recombinant plasmids were constructed to produce a recombinant protein vaccine and DNA vaccine system. Overexpressed proteins were determined to be 30 kDa and 25 kDa in the E. coli and TK1 systems, respectively. The efficacy of the chimeric multiepitope construct as a recombinant protein vaccine and DnA vaccine was evaluated in nile tilapia, followed by S. agalactiae challenge at 1 × 10 7 cfU/mL. Relative percentage survival (RpS) and cumulative mortality were recorded at approximately 57-76% and 17-30%, respectively. These chimeric multiepitope vaccines should be applied in streptococcosis disease control and developed into a multivalent vaccine to control multiple diseases.

show abstract

Section: Discussionsupporting

confidence: 65%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

“…island (PI)-1 ancillary protein 1 15 , CAMP factor, R5 protein, enolase, hemolysin (cyLE) 16 , fibrinogen-binding protein A (FbsA) 17 , and surface immunogenic protein (Sip) 14 .…”

mentioning

confidence: 99%

See 3 more Smart Citations

Novel Chimeric Multiepitope Vaccine for Streptococcosis Disease in Nile Tilapia (Oreochromis niloticus Linn.)

Pumchan

Krobthong

Roytrakul

et al. 2020

Sci Rep

View full text Add to dashboard Cite

show abstract

Biopolymer‐based Carriers for DNA Vaccine Design

et al. 2021

View full text Add to dashboard Cite

She studied chemistry at the University of Zagreb, and completed her PhD at the University of Strathclyde,G lasgow,w orking on DNA detection by advanced spectroscopies, such as SERRS. After postdoc research on DNA nanostructuring and artificial enzyme design at the University of Dortmund,s he was agroup leader at Karlsruhe Institute of Technology before joining Cambridge. Her research focuses on nanostructured biomaterials for use in photocatalysis and targeted drug delivery.

show abstract